Women with acute chest pain get different levels of care than men

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Observational study: A study in which the subject is observed to see if there is a relationship between two or more things (eg: the consumption of diet drinks and obesity). Observational studies cannot prove that one thing causes another, only that they are linked.

People: This is a study based on research using people.

There is a significant variation in the care women with acute chest pain receive compared to men, and strategies to reduce these differences should be strongly considered by doctors and policymakers, according to Australian research. The study looked at everyone who needed emergency medical services for acute chest pain in Victoria, over 4.5 years and it found that women were less likely to receive care that followed guidelines in both prehospital and hospital settings. Similarly, women with acute coronary syndrome were less likely to undergo angiography or be admitted to a cardiac or intensive care unit. It also found that mortality was higher for women diagnosed with a dangerous type of heart attack, known as an ST-segment elevation myocardial infarction (STEMI), but lower overall. 

Journal/conference: Journal of the American College of Cardiology

Link to research (DOI): 10.1016/j.jacc.2022.12.025

Organisation/s: Monash University, Baker Heart and Diabetes Institute, The Alfred Hospital

Funder: The study was supported by Ambulance Victoria and the Department of Cardiology, Alfred Health. Drs Dawson and Bloom are supported by National Health and Medical Research Council of Australia (NHMRC) and National Heart Foundation (NHF) postgraduate scholarships. Dr E. Nehme is supported by an NHMRC postgraduate scholarship. Dr Z. Nehme is supported by an NHF fellowship. Drs Taylor, Kaye, and Smith are supported by NHMRC grants. Dr Stub is supported by NHF grants. Dr Nicholls has received research support from AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfrareDx, Roche, Sanofi-Regeneron, and LipoScience; and has been a consultant for AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Vaxxinity, and Sequiris

Attachments:

Note: Not all attachments are visible to the general public

  • American College of Cardiology
    Web page
    Please link to the article in online versions of your report (the URL will go live after the embargo ends).
  • American College of Cardiology
    Web page
    Please link to the article in online versions of your report (the URL will go live after the embargo ends).

News for:

Australia
VIC

Media contact details for this story are only visible to registered journalists.